| Objective:To evaluate the safety and efficacy of intravitreal bevacizumab injection in patients with exudative age-related macular degeneration (AMD).Methods:The records of patients treated with intravitreal injection of 2.5mg bevacizumab for AMD were retrospectively reviewed. All patients were evaluated by complete ophthalmic examination, optical coherence tomography and fluorescein and/or indocyanine green angiography. Repeated treatment with intravitreous bevacizumab occurred if there were signs of persistent or recurrent exudation. Changes in best corrected visual acuity (BCVA), central foveal thickness (CFT) and total macular volume (TMV) over at least 6 months were the main outcome measures.Results:Thirty eyes of 30 patients (21 males and 9 females) with the average of 72 years were included. The mean baseline BCVA, CFT and TMV were 1.03±0.55 (logMAR),364.97±151.83μm and 8.36±1.84mm3, respectively. Although there was no significant decreased in mean CFT and TMV one week after the injection,+he mean BCVA had improvement significantly (logMAR,0.79±0.33; p= 0.02). At the last visit of 9.7 months follow up (data available for 30 eyes), BCVA (logMAR, 0.70±0.40; p=0.004), CRT (272.93±81.06; p=0.05) and TMV (7.20±0.98; p=0.004) showed significant improvements over baseline values. BCVA was improved by at least two lines in 18 eyes (60%), remained stable in 8 eyes (26.7%) at the last visit. A total of 58 injections were performed and the average number of injections was 1.93 in the group. About 50% of re-injections gained at least two lines of vision improvement one week following the re-treatment. No serious ocular or systemic adverse events were observed.Conclusions:Intravitreal injection of bevacizumab for exudative AMD was well tolerated with an improvement in BCVA, CFT and TMV over the mean 9.7 months follow-up period. Re-injection of intravitreal bevacizumab should be administered as needed.
|
PDF Full Text Request